(Solid Tumors) Is the RET Inhibitor Pralsetinib Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- May 29, 2020
- Read time: 1 minute
From May 29–31, 2020, Vivek Subbiah presented at the ASCO 2020 Virtual Meeting "Efficacy and safety results of RET inhibitor pralsetinib (BLU-667) monotherapy in advanced solid tumor patients with RET fusion genes in the ARROW Phase 1/2 clinical trial."
The ARROW Phase 1/2 clinical trial evaluated pralsetinib (BLU-667) 30–600 mg administered once or twice daily in advanced solid tumor patients with RET fusion genes. The primary endpoint was objective response rate.
Patients enrolled in this trial included: 16 patients with papillary carcinoma, 1 with anaplastic thyroid cancer, 3 with pancreatic cancer, 3 with colorectal cancer, and 6 with other cancer types.
Trial results for the primary endpoint objective response rate were: thyroid cancer group 75% (N=9/12), other cancer types (N=3/5). Median duration of response was: thyroid cancer group 14.5 months, other cancer types (N=2 patients: 11.5 months and 19.3 months respectively).
Regarding safety, adverse events confirmed in the majority of patients included: AST elevation 31%, anemia 22%, ALT elevation 21%, constipation 21%, and hypertension 20%. The treatment discontinuation rate due to adverse events was 4%.
Based on the ARROW trial results, Vivek Subbiah concluded: In advanced solid tumor patients with RET fusion genes, pralsetinib (BLU-667) monotherapy demonstrated favorable and durable antitumor activity not only in non-small cell lung cancer but also in other advanced solid tumors.
[Important Note] Medical Supporter's translations of overseas clinical trial data and pharmaceutical information are not intended to encourage participation in clinical trials or use of new drugs. The translated information is for reference only and not intended as medication guidelines. Please discuss with healthcare professionals and refer to the original text below the article for accurate information.
Source: Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. (2020 ASCO Virtual Scientific Program, Abstract No: 109)
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4